Herpes zoster in immunocompromised patients: incidence, timing, and risk factors

PK Wung, JT Holbrook, GS Hoffman, AK Tibbs… - The American journal of …, 2005 - Elsevier
PURPOSE: To evaluate the risk factors for herpes zoster as well as the incidence and timing
of this complication in patients who were treated with immunosuppression because of active …

Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis

PK Wung, T Anderson, KR Fontaine… - Arthritis Care & …, 2008 - Wiley Online Library
Objective Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and
health implications of changes in weight that occur during the treatment of inflammatory …

Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon

A Fava, PK Wung, FM Wigley… - Arthritis care & …, 2012 - Wiley Online Library
Abstract Objective The RhoA/Rho kinase pathway plays a pivotal role in cold‐induced
vasoconstriction, vascular smooth muscle cells function, and vascular homeostasis. This …

Therapeutics of Wegener's granulomatosis

PK Wung, JH Stone - Nature Clinical Practice Rheumatology, 2006 - nature.com
The treatment of Wegener's granulomatosis, one of the most common forms of systemic
vasculitis, has changed substantially over the past two decades. The principal aims of …

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

D Van Der Heijde, A Deodhar, WP Maksymowych… - RMD open, 2022 - rmdopen.bmj.com
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing
spondylitis (AS) has not been previously reported. Methods In SELECT-AXIS 1, patients …

An atypical complication of atypical pneumonia

ES Antonarakis, PK Wung, DJ Durand… - The American journal …, 2006 - amjmed.com
A previously healthy 45-year-old African-American man presented to the hospital with a 1-
week history of malaise, fatigue, anorexia, fever, and rigors. He reported temperatures …

Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies

PK Wung, JM Guettier - Scleroderma: From Pathogenesis to …, 2024 - Springer
Drug discovery and development is an expensive and risky endeavor. It is estimated that
only 10–15% of therapeutic compounds that enter clinical development ever reach the …

“Still” Ill?

PK Wung, MR Pipeling, FM Wigley - The American journal of medicine, 2008 - amjmed.com
Our patient was a 59-year-old Caucasian man who had been in good health until 4 months
prior to presentation. Then, he developed daily high fevers, drenching night sweats, malaise …

Taking a practical approach to giant cell arteritis

PK Wung, JH Stone - The Journal of Musculoskeletal …, 2008 - search.proquest.com
Giant cell arteritis (GCA) is a major cause of vision loss and other health problems. Classic
histopathological findings include transmural inflammation with mononuclear cells and …

Painful digital ulcers in a scleroderma patient with Raynaud's phenomenon

FM Wigley, PK Wung - Case Studies in Systemic Sclerosis, 2011 - Springer
Raynaud's phenomenon (RP) is seen in over 95% of patients with SSc and is often the first
symptom of the disease. Scleroderma vascular disease is secondary to an obliterative …